INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, has announced equity grants under its 2022 Inducement Plan. The Compensation Committee approved awards to two newly hired employees, including:
1. Restricted stock units (RSUs) covering 1,526 shares of common stock
2. Options to purchase 1,600 shares of common stock
The grants, dated September 30, 2024, include RSUs vesting over three years and stock options with an exercise price of $5.78. The stock options will vest in four installments, with one-fourth vesting immediately and the remainder annually over three years. Both RSUs and options are subject to continued employment and specific agreement terms under the Inducement Plan.
INOVIO (NASDAQ:INO), un'azienda biotecnologica focalizzata su farmaci a base di DNA per malattie correlate all'HPV, cancro e malattie infettive, ha annunciato concessioni di azioni nell'ambito del suo Piano di Induzione 2022. Il Comitato per la Compensazione ha approvato premi per due nuovi assunti, tra cui:
1. Unità azionarie vincolate (RSUs) relative a 1.526 azioni ordinarie
2. Opzioni di acquisto di 1.600 azioni ordinarie
Le concessioni, datate 30 settembre 2024, includono RSUs che maturano nell'arco di tre anni e opzioni su azioni con un prezzo di esercizio di 5,78 dollari. Le opzioni su azioni matureranno in quattro rate, con un quarto che matura immediatamente e il resto annualmente nel corso di tre anni. Sia le RSUs che le opzioni sono soggette a un'occupazione continuativa e a specifici termini di accordo ai sensi del Piano di Induzione.
INOVIO (NASDAQ:INO), una empresa biotecnológica centrada en medicamentos de ADN para enfermedades relacionadas con el VPH, cáncer y enfermedades infecciosas, ha anunciado concesiones de acciones bajo su Plan de Inducción 2022. El Comité de Compensación aprobó premios para dos empleados recién contratados, incluyendo:
1. Unidades de acciones restringidas (RSUs) que cubren 1.526 acciones ordinarias
2. Opciones de compra de 1.600 acciones ordinarias
Las concesiones, fechadas el 30 de septiembre de 2024, incluyen RSUs que se consolidan durante tres años y opciones sobre acciones con un precio de ejercicio de 5,78 dólares. Las opciones se consolidarán en cuatro pagos, con un cuarto que se consolida de inmediato y el resto anualmente durante tres años. Tanto las RSUs como las opciones están sujetas a empleo continuo y a términos de acuerdo específicos bajo el Plan de Inducción.
INOVIO (NASDAQ:INO)는 HPV 관련 질병, 암 및 감염병을 위한 DNA 의약품에 집중하는 생명공학 회사로, 2022 유도 계획에 따른 주식 보상을 발표했습니다. 보상 위원회는 새로 고용된 두 명의 직원에 대한 상여를 승인했습니다. 상여 내역은 다음과 같습니다:
1. 제한 주식 단위 (RSUs) 1,526주에 대한 것
2. 주식 구매 옵션 1,600주에 대한 것
이 보상은 2024년 9월 30일자로, 3년에 걸쳐 만료되는 RSUs와 주당 5.78달러의 행사가격으로 주식 옵션이 포함됩니다. 주식 옵션은 4회에 걸쳐 만료되며, 1/4는 즉시 만료되고 나머지는 3년에 걸쳐 매년 만료됩니다. RSUs와 옵션 모두는 지속적인 고용과 유도 계획에 따른 특정 계약 조건에 따라 적용됩니다.
INOVIO (NASDAQ:INO), une entreprise de biotechnologie axée sur les médicaments à base d'ADN pour les maladies liées au VPH, le cancer et les maladies infectieuses, a annoncé des attributions d'actions dans le cadre de son Plan d'Induction 2022. Le Comité de Rémunération a approuvé des récompenses pour deux nouveaux employés, comprenant :
1. Unités d'actions restreintes (RSUs) couvrant 1.526 actions ordinaires
2. Options d'achat de 1.600 actions ordinaires
Les attributions, datées du 30 septembre 2024, comprennent des RSUs acquises sur trois ans et des options sur actions avec un prix d'exercice de 5,78 $. Les options sur actions seront acquises en quatre versements, un quart étant acquis immédiatement et le reste annuellement sur trois ans. Les RSUs et les options sont tous deux soumis à un emploi continu et à des conditions d'accord spécifiques dans le cadre du Plan d'Induction.
INOVIO (NASDAQ:INO), ein biotechnologisches Unternehmen, das sich auf DNA-Medikamente für HPV-assoziierte Krankheiten, Krebs und ansteckende Krankheiten konzentriert, hat Aktienvergaben im Rahmen seines Induktionsplans 2022 bekannt gegeben. Der Vergütungsausschuss genehmigte Auszeichnungen für zwei neu eingestellte Mitarbeiter, dazu gehören:
1. Eingeschränkte Aktieneinheiten (RSUs), die 1.526 Aktien des Stammkapitals abdecken
2. Optionen zum Kauf von 1.600 Aktien des Stammkapitals
Die Zuschüsse, datiert auf den 30. September 2024, umfassen RSUs, die über drei Jahre aufgeschlüsselt werden, und Aktienoptionen mit einem Ausübungspreis von 5,78 USD. Die Aktienoptionen werden in vier Tranchen ausbezahlt, wobei ein Viertel sofort fällig wird und der Rest jährlich über drei Jahre. Sowohl RSUs als auch Optionen sind an eine fortgesetzte Beschäftigung und spezifische Vereinbarungsbedingungen im Rahmen des Induktionsplans gebunden.
- Attracting new talent with equity incentives
- Aligning employee interests with company performance through stock-based compensation
- Potential dilution of existing shareholders' equity
The Compensation Committee of INOVIO's Board of Directors has approved the awards of restricted stock units ("RSU"s) covering an aggregate of 1,526 shares of common stock and options to purchase an aggregate of 1,600 shares of common stock, each with a grant date of September 30, 2024 (the "Grant Date"), to two newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The stock options have an exercise price of
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, jennie.willson@inovio.com
Investors: Thomas Hong, (267) 440-4298, thomas.hong@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grants-under-inducement-plan-302265897.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What equity grants did INOVIO (INO) announce on October 2, 2024?
What is the vesting schedule for the RSUs granted by INOVIO (INO)?
What is the exercise price of the stock options granted by INOVIO (INO) on September 30, 2024?
How will the stock options granted by INOVIO (INO) vest?
